Real-world outcomes of neoadjuvant targeted therapy in resectable epidermal growth factor receptor mutation-positive non-small cell lung cancer: a retrospective study
Background Multiple clinical trials have validated the efficacy of neoadjuvant targeted therapy (NTT) for resectable non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. This retrospective study aimed to assess the efficacy and safety of neoadjuvant EGFR-tyrosine kinase inhibi...